| | | Age | Sex | Hematuria | Proteinuria (g/day) | Serum creatinine (mg/dL) | ANA | Anti-dsDNA (UL/mL) | Low C3/C4 | ANCA specificity | Renal biopsy | Positive immunenoreactanats | Diagnosis | Treatment |
| | Case 1 of [1] | 22 | Female | Yes | 1.5 | 2.7 | Positive (1:1286) | Negative | Not determined | MPO-ANCA | | IgG 3+ IgM 2+ IgA+ C3 3+ C1q 2+ | LN IV-S (A/C)/ANCA GN | Intavenous CY, PSL, MMF | | Case 2 of [1] | 37 | Female | Yes | 5.9 | 10 | Positive (1:80) | Positive | Not determined | MPO-ANCA | | IgG 3+ C3 3+ C1q 1+ | LN V/ANCA GN | IntravenousCY.PSL, azathioprine | | Case 3 of [1] | 62 | Female | Yes | 2 | 4.7 | Positive (1:848) | Positive | Not determined | Negative | | IgG+ IgM+ C3 2+ | LN III (A/C)/ANCA GN | IntravenousCY, PSL | | Case 4 of [1] | 80 | Female | Yes | 4 | 4.5 | Positive (1:2560) | Negative | Not determined | Negative | | IgG+ IgM+ | LN II/ANCA GN | Hydralazine, oral CY, PSL, PLX | | Case 5 of [1] | 19 | Male | Yes | 4 | 9.6 | Positive (1:160) | Positive | Not determined | Negative | | IgG 3+ IgA+ C3 2+ C1q 2+ | LN IV G (A)/ANCA vasculitis | M-PRED, intavenous CY, oral CY, PSL | | Case 6 of [1] | 50 | Female | Yes | 3.2 | 4.4 | Positive (1:160) | Negative | Not determined | MPO-ANCA | | IgG3+ IgA+ C3 2+ C1q 2+ | LN III (A)/ANCA GN | M-PRED, intravenous CY, PSL | | Case 7 of [1] | 55 | Male | Yes | 3 | 21 | Positive (1:160) | Positive | Not determined | Negative | | IgG 2+ C3 2+ | LN V /ANCA GN | PSL,intravenous CY | | Case 8 of [1] | 37 | Female | Yes | 6.4 | 1.1 | Positive (1:40) | Negative | Not determined | MPO-ANCA | | IgG 3+ C3 2+ | LN V /ANCA GN | IntravenousCY, PSL | | Case 9 of [1] | 44 | Female | Yes | 1.7 | 8.8 | Positive (1:320) | Positive | Not determined | Negative | | IgG 2+ IgM 1+ IgA 1+ C3 2+ | LN III (A/C)/ANCA GN | IntravenousCY, PSL,MMF, HC | | Case 10 of [1] | 78 | Female | Yes | 3 | 4.5 | Positive (1:640) | Negative | Not determined | MPO-ANCA,PR-3 ANCA | | IgG 2+ C3 2+ | LN III(A/C)/ANCA GN | Hydralazine, M-PRED, OSL, oral CY | | [4] | 40 | Female | Not determined | Not determined | 8.7 | Positive (1:640) | Negative | Not determined | MPO-ANCA | | Not determined | Pauci-immune GN | PSL, rituximab, HC, CY | | [5] | 48 | Female | Yes | 0.6 | Not determined | Positive (1:40) | Negative | No/no | PR3-ANCA | | IgG+ C3+ | LN V | PSL, intravenous CY | | Case 1 of [3] | 23 | Female | Yes | 0.8 | 1.02 | Positive (1:800) | 23 | No/yes | Negative | | C3+ | Pauci-immune GN | Not determined | | Case 2 of [3] | 43 | Female | Yes | 3.2 | 7.11 | Positive (1:1280) | Negative | No/no | MPO-ANCA | | IgG+ IgM+ C3+ | Pauci-immune GN | Not determined | | Case 3 of [3] | 57 | Female | Yes | 3.6 | 5.63 | Positive (1:1280) | Negative | No/no | MPO-ANCA | | Pauci-immune | Pauci-immune GN | Not determined | | Case 4 of [3] | 29 | Female | Yes | 0.3 | 1.01 | Positive (1:640) | 20 | No/no | MPO-ANCA | | IgG 3+ IgM 2+ C1q 2+ | LN II-G | Not determined | | Case 5 of [3] | 41 | Female | Yes | 4 | 1.53 | Positive (1:2560) | 50 | Yes/yes | MPO-ANCA | | IgG 2+ IgA 2+ C3 3+ C1q 2+ | LN IV-G | Not determined | | Case 6 of [3] | 53 | Female | Yes | 6 | 1.62 | Positive (1:600) | Negative | Yes/yes | MPO-ANCA | | Negative | Pauci-immune GN | Not determined | | Case 7 of [3] | 27 | Female | Yes | 0.8 | 3.93 | Positive (1:200) | 22 | No/yes | MPO-ANCA | | IgG+ C3+ | Pauci-immune GN | Not determined | | Case 8 of [3] | 74 | Female | Yes | 1 | 3.31 | Positive (1:5240) | 50 | No/no | MPO-ANCA | | IgG 2+ C3 2+ | LN IV-G | Not determined | | Case 1 of [4] | 74 | Female | Yes | 0.6 | 4.1 | Positive (1:5120) | Positive | No/yes | MPO-ANCA | | IgG+ IgM+ C3+ | Not determined | Not determined | | Case 2 of [4] | 35 | Female | Yes | ＞6 | 3.4 | Positive (1:620) | Positive | No/no | MPO-ANCA | | IgG+ | Not determined | PSL, CY | | Case 3 of [4] | 21 | Female | Yes | 2.5 | 3.8 | Positive (1:2560) | Positive | No/no | MPO-ANCA | | IgG+ IgM+ C3+ C1q+ | Not determined | PSL, oral CY, intravenous CY |
|
|
ANA: antinuclear antibody, ANCA: antineutrophil cytoplasmic antibodies, LN: lupus nephritis, GN: glomerulonephritis, CY: cyclophosphamide, MMF: mycophenolate mofetil, PSL: prednisolone, M-PRED: pulse methylprednisolone, PLX: plasmapheresis, and HC: hydroxychloroquine.
|
